Leerink Partnrs Has Positive Outlook of LXEO FY2026 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Investment analysts at Leerink Partnrs boosted their FY2026 earnings estimates for Lexeo Therapeutics in a research note issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($2.54) for the year, up from their prior estimate of ($2.55). The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ FY2027 earnings at ($2.50) EPS.

A number of other research analysts have also recently issued reports on the stock. HC Wainwright increased their target price on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, November 14th. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday, January 21st. Chardan Capital raised their price objective on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Leerink Partners dropped their price objective on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Wednesday, November 13th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Lexeo Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $23.80.

Lexeo Therapeutics Trading Down 0.5 %

Shares of Lexeo Therapeutics stock opened at $5.58 on Friday. Lexeo Therapeutics has a 12-month low of $4.67 and a 12-month high of $19.50. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The stock has a market cap of $184.51 million, a PE ratio of -1.77 and a beta of 3.08. The company has a 50-day moving average of $6.64 and a two-hundred day moving average of $9.21.

Institutional Trading of Lexeo Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in shares of Lexeo Therapeutics by 86.5% in the 3rd quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock valued at $5,003,000 after purchasing an additional 256,635 shares during the last quarter. State Street Corp boosted its holdings in shares of Lexeo Therapeutics by 29.4% in the 3rd quarter. State Street Corp now owns 253,946 shares of the company’s stock valued at $2,296,000 after purchasing an additional 57,674 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new position in shares of Lexeo Therapeutics in the 3rd quarter valued at $11,307,000. Barclays PLC boosted its holdings in shares of Lexeo Therapeutics by 162.2% in the 3rd quarter. Barclays PLC now owns 50,210 shares of the company’s stock valued at $454,000 after purchasing an additional 31,057 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in shares of Lexeo Therapeutics by 18.9% in the 3rd quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock valued at $33,997,000 after purchasing an additional 599,203 shares during the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.